Publications
Articles, papers and letters by Anthony Cox. Links given when available.
Publications
Cox AR, Langford N. Drug-induced cardiac failure. Adverse Drug Reaction Bulletin. 2003;220:843-846.
Anton C, Cox AR, Watson RDS, Ferner RE. The safety of spironolactone treatment in patients with heart
failure. Journal of Clinical Pharmacy & Therapeutics. 2003;28(4):285-287.
[Abstract]
Cox AR, The war on the web: Googlebomb of mass destruction. The Guardian. 10th July 2003.
[text]
Kerr KL, Higham C, Cox AR, Situnayake RD. A determination of patient awareness of the safety issues surrounding treatment with methotrexate.
The Pharmaceutical Journal 2003;271:900-901.
[PDF]
Cox AR. Let us be called the Royal Society of Pharmacists of Great Britain. The Pharmaceutical Journal 2003;271:44.
[text]
[PDF]
Cox AR. Manufacturers should make reading labels easier. The Pharmaceutical Journal 2003;270:514.
[text]
Cox AR, Anton C. Report [...] drug reactions with warfarin. The Pharmaceutical Journal 2003;270:366-367.
[text]
Cox AR. Advertising: Prescribers need appraisal training programmes. The Pharmaceutical Journal 2003;270:154.
[text]
Whitaker S, Cox AR, Alexander AM. Internet networking for pharmacists: an evaluation of a mailing list for UK
pharmacists. International Journal of Pharmacy Practice. 2003;11:25–32.
[Abstract]
Anton CA, Cox AR, Ferner RE. Using trade names: sometimes it helps.
Archives of Internal Medicine 2003 ;
162
: 2636.
Cox AR, Dent SN. Warfarin: Risks not always easy to evaluate.
British Medical Journal
Electronic response
[text]
Anton C, Cox AR. More data are needed.
British Medical Journal
Electronic response
[text]
Dent SN, Cox AR, Marriott JF, Langley CA, Wilson KA. Warfarin toxicity: do
discharge ICD-codes and yellow cards accurately identify serious adverse drug
reactions?
The International Journal of Pharmacy Practice.
2002;
10(suppl)
:R40.
[PDF]
Cox AR. Systemic effects of ocular drugs.
Adverse Drug Reaction Bulletin.
2002;
215
:823-826.
Langford NJ, Cox AR. Medication errors: Over reliance on any safety system is
not ideal.
The Pharmaceutical Journal.
2002;
269
:248.
[text]
Rippengill KL, Higham C, Cox Ar, Situnayake RD. Methotrexate - patient
awareness and safety issues.
Pharmacy World & Science.
2002;
24(3)
:A21.
Cox AR. Embracing ADR reporting could improve pharmacists' standing.
The Pharmaceutical Journal
2002;
269
:14.
[text]
[PDF]
Cox A, Jenkins A. A case of carboplatin hypersensivity.
Pharmacy in Practice
2002;
12(5)
:187.
Cox A, Millane T. An adverse drug reaction as a consequence of error.
Pharmacy in Practice
2002;
12(2)
:84-86.
Cox AR, Marriott JF. Take a spoonful of sugar with salt.
The Hospital Pharmacist
2002;
9(4)
:90.
[text]
Cox A. Childhood vaccination, a social responsibility.
The Pharmaceutical Journal
2002;
268
:570.
[text]
Cox A, Book Review - Martindale 33rd edition.
The Pharmaceutical Journal
2002;
268
:505.
[text]
Cox A, Overwhelming evidence for safety of MMR.
The Pharmaceutical Journal
2002;
268
:398.
[text]
Cox AR. Marriott JF. Safety First.
Pharmaceutical Marketing
February 2002
[text]
Jenkins A, Cox A. Influenza vaccine and warfarin.
Pharmacy in Practice
2002;
12(1)
:140.
Cox A. Humans are fallible machines.
British Medical Journal
Electronic response
[text]
Cox A. Syncope as a possible adverse drug reaction.
Pharmacy in Practice
2001;
11(9)
:286.
Cox A, Underhill J. New Drugs must be prescribed judiciously.
The Pharmaceutical Journal
2001;
267
:646-647.
[text]
Cox A. What about side effects and contraindications?
The Pharmaceutical Journal
2001;
267
:425.
[text]
Cox A, Anton C. Safety profile of bupropion for chronic obstructive pulmonary
disease.
The Lancet
2001;
358
:1010.
Cox A, Anton C, Goh CHF, Easter M, Langford NJ, Ferner RE. Adverse drug
reactions in patients admitted to hospital indentified by discharge ICD-10
codes and by spontaneous reports.
British Journal of Clinical Pharmacology
2001;
52
:337-339.
Bradley M.J, Cox A. Suspected interaction betweeen celecoxib and warfarin.
Pharmacy in Practice
2001;
11(8)
:243-245.
Anton C, Cox A. In some respects, yes.
British Medical Journal
Electronic response
[text]
Anton C, Cox A. Adverse Drug reactions.
British Journal of General Practice.
2001;
51(468)
:582-683.
[text]
Cox A, Anton C, Ferner R. Take care with Zyban. The Pharmaceutical Journal.
2001;
266
:718-722.
[text]
Cox AR, Marriott J. Is self-checking (by anyone) a risk too far?
The Pharmaceutical Journal
2001;
266
:814.
[text]
Cox AR. Hypokalaemia associated with the use of spironolactone in heart
failure.
Pharmacy in Practice.
2001;
11(6)
:187-189.
Cox AR, Barnett AL. Reporting reactions to newly marketed drugs.
Pharmacy in Practice.
2001;
11(4)
:121-122.
Mundia AN, Cox AR, Marriott JF. Discordance: coronary care patient's knowledge
of Medicines.
GHP
. 2001;
2(2)
:14.
Cox AR. What can hospital pharmacy do to increase adverse drug reaction
reporting.
Pharmacy in Practice
. 2001;
11(3)
:84.
Cox AR. Haematoma associated with tirofiban and enoxaparin in an unstable
angina patient.
Pharmacy in Practice
. 2001;
11(3)
:87-88.
Cox AR. Adverse reactions to intra-vascular radiological contrast media.
Pharmacy in Practice
. 2001;
11(2)
:54-55.
Cox AR, McCarthy J. Hepatic adverse drug reactions.
Pharmacy in Practice.
2000;
11(1)
:18-19.
Cox AR, Fox H. Split and merge: a way forward for the Royal Pharmaceutical
Society.
The Pharmaceutical Journal
2000;
265
:263.
[text]
Cox AR, Barrett J. Identifying adverse drug reactions in the ICU.
Pharmacy in Practice
. 2000;
10(9)
: 322-4.
Cox AR, Townsend T. Reporting well-known reactions.
Pharmacy in Practice.
2000;
10(8)
: 288-90.
Cox AR. Elite II: Caution required
The Pharmaceutical Journal.
2000;
263
:858.
[text]
Cox AR. The pharmacist's role in adverse drug reactions.
Pharmacy in Practice
. 2000;
10(7)
: 262-3.
Cox AR. The Committee on Safety of Medicine's Yellow Card Scheme.
Pharmacy in Practice.
2000;
10(6)
: 213-15.
Cox AR, Marriott J. Dealing with dispensing errors.
The Pharmaceutical Journal
. 2000;
264
:724.
[text]
Cox AR. Pharmacovigilance: Why reports are anonymous
The Pharmaceutical Journal.
1999;
263
:784.
[text]
Other articles and letters
Cox AR. The Society: Membership approval
The Pharmaceutical Journal.
2003;
271
:175.
[text]
Cox AR. An opportunity to move forward.
The Pharmaceutical Journal.
2003;
270
:858.
[text]
Cox A. The Society: Knocking down a straw man
The Pharmaceutical Journal.
2002;
269
:100.
[text]
Cox A. A way forward for the Society?
Pharmacy Magazine.
2002;
June issue
:8
Cox A. Time to bring clarity to the representation debate
The Pharmaceutical Journal.
2002;
268
:140.
[text]
Cox A. Access to reports of the statutory committee.
.
The Pharmaceutical Journal.
2001;
267
:321-324.
[text]
Cox A. Leadership requires listening.
The Pharmaceutical Journal.
2001;
266
:852-856.
[text]
Fox HR,Cox AR. Some changes are inevitable.
The Pharmaceutical Journal.
2001;
265
:855.
[text]
Cox AR. Finance concern.
The Pharmaceutical Journal.
2000;
265
:754.
[text]
Cox AR. Parish Magazine.
The Pharmaceutical Journal.
2000;
265
:443.
[text]
Fox HR, Cox AR. Separation of functions
.
The Pharmaceutical Journal.
2000;
265
:394.
[text]
Cox AR. e-pharmacy: ethereal pharmacy?
Chemist and Druggist
2000;
30 September 2000
:8
Whitaker S, Cox AR, Alexander AM The members, the medium and the message: an
evaluation of Private-Rx, the information network for UK pharmacists.
The Pharmaceutical Journal
2000;
265
:R73. (suppl British Pharmaceutical Conference, Birmingham)
[text]
Cox AR. Breaking the deadlock.
The Pharmaceutical Journal.
2000;
265
:363.
[text]
Cox AR, Whitaker S. Protecting the legacy.
The Pharmaceutical Journal.
2000;
265
:160.
[text]
Cox AR. Cat Mat Publicity
The Pharmaceutical Journal.
2000;
264
:655.
[text]
Nebrensky C, Cox AR, Burgess P, Haynes S, Wong LS, Young J, et al.. Who
authorised flat purchase?
The Pharmaceutical Journal.
2000;
264
:589.
[text]
Phillips G, Cox AR, Eyles R, Fox H, Whitaker S, Curtis S, et al.. More details
please
The Pharmaceutical Journal.
2000;
264
:402-403.
[text]
Cox AR. Electing the Council
The Pharmaceutical Journal.
1999;
263
:349.
[text]